Allergan PLC. (AGN) Given a $285.00 Price Target at Royal Bank Of Canada
Allergan PLC. (NYSE:AGN) has been assigned a $285.00 target price by equities researchers at Royal Bank Of Canada in a research note issued on Thursday. The firm presently has a “buy” rating on the stock. Royal Bank Of Canada’s price objective suggests a potential upside of 17.45% from the company’s previous close.
AGN has been the subject of several other research reports. Cowen and Company set a $400.00 price objective on Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. Mizuho decreased their price objective on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Cantor Fitzgerald started coverage on Allergan PLC. in a report on Friday, June 16th. They set a “neutral” rating and a $231.00 price objective for the company. Finally, Zacks Investment Research upgraded Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a report on Tuesday, July 11th. Seven analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $274.14.
Shares of Allergan PLC. (NYSE:AGN) traded down 3.08% during trading on Thursday, hitting $242.65. 3,014,756 shares of the stock traded hands. The firm has a market cap of $81.50 billion, a P/E ratio of 7.56 and a beta of 1.16. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The company has a 50-day moving average of $245.21 and a 200-day moving average of $237.12.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.35 earnings per share. On average, analysts forecast that Allergan PLC. will post $16.10 EPS for the current fiscal year.
In related news, Director Nesli Basgoz sold 1,889 shares of the company’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.36% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Crestwood Advisors Group LLC acquired a new position in Allergan PLC. during the first quarter valued at $103,000. Feltz Wealth PLAN Inc. acquired a new position in Allergan PLC. during the first quarter valued at $107,000. Enterprise Financial Services Corp boosted its position in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares in the last quarter. Jacobi Capital Management LLC boosted its position in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares in the last quarter. Finally, JNBA Financial Advisors boosted its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares in the last quarter. 84.66% of the stock is currently owned by institutional investors and hedge funds.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.